Gastroenterology
Volume 136, Issue 3 , Pages 780-798, March 2009

Mouse Models of Colon Cancer

  • Makoto Mark Taketo

      Affiliations

    • Department of Pharmacology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    • Corresponding Author InformationReprint requests Address requests for reprints to: Makoto Mark Taketo, MD, PhD, Department of Pharmacology, Graduate School of Medicine, Kyoto University, Yoshida-Konoé-cho, Sakyo, Kyoto 606-8501, Japan or Winfried Edelmann, PhD, Department of Cell Biology, Albert Einstein College of Medicine, 1301 Morris Park Avenue, Bronx, New York 10461
  • ,
  • Winfried Edelmann

      Affiliations

    • Department of Cell Biology, Albert Einstein College of Medicine, Bronx, New York
    • Corresponding Author InformationReprint requests Address requests for reprints to: Makoto Mark Taketo, MD, PhD, Department of Pharmacology, Graduate School of Medicine, Kyoto University, Yoshida-Konoé-cho, Sakyo, Kyoto 606-8501, Japan or Winfried Edelmann, PhD, Department of Cell Biology, Albert Einstein College of Medicine, 1301 Morris Park Avenue, Bronx, New York 10461

Received 11 September 2008; accepted 12 December 2008.

John P. Lynch and David C. Metz, Section Editors

Genetically engineered mice are essential tools in both mechanistic studies and drug development in colon cancer research. Mice with mutations in the Apc gene, as well as in genes that modify or interact with Apc, are important models of familial adenomatous polyposis. Mice with mutations in the β-catenin signaling pathway have also revealed important information about colon cancer pathogenesis, along with models for hereditary nonpolyposis colon cancer and inflammatory bowel diseases associated with colon cancer. Finally, transplantation models (xenografts) have been useful in the study of metastasis and for testing potential therapeutics. This review discusses what models have been developed most recently and what they have taught us about colon cancer formation, progression, and possible treatment strategies.

Abbreviations used in this paper: COX, cyclooxygenase, FAP, familial adenomatous polyposis, HNPCC, hereditary nonpolyposis colon cancer, IDL, insertion/deletion mutation, IL, interleukin, LOH, loss of heterozygosity, MMR, mismatch repair, MNNG, N-methyl-N′-nitro-N-nitrosoguanidine, MSI, microsatellite instability, SNP, single nucleotide polymorphism, TGF, transforming growth factor, TLR, Toll-like receptor

 

 Conflicts of interest The authors disclose no conflicts.

 Funding The research programs in the Edelmann laboratory were supported by National Institutes of Health grants CA76329, CA93484, CA84301, and CA13330, and the research programs in the Taketo laboratory were supported by grants from the Ministry of Education, Science, Sports, and Culture, Japan; Organization for Pharmaceutical Safety and Research, Japan; University of Tokyo–Banyu Pharmaceutical Co Joint Fund; Takeda Foundation; Mitsubishi Foundation; Sagawa Cancer Research Foundation; and a Littlefield-AACR Colon Cancer Metastasis Research Grant.

PII: S0016-5085(08)02307-X

doi:10.1053/j.gastro.2008.12.049

Gastroenterology
Volume 136, Issue 3 , Pages 780-798, March 2009